Alnylam Pharmaceut (ALNY) 69.17 $ALNY Research
Post# of 273323
Posted On: 09/03/2016 11:17:51 AM
Alnylam Pharmaceut (ALNY) 69.17 $ALNY
Research Reports Initiation on Biotech Stocks -- Hemispherx Biopharma, Vascular Biogenics, BioCryst Pharma, and Alnylam Pharma
PR Newswire - Mon Aug 29, 7:00AM CDT
The Biotech industry is focused on novel drug development and clinical research aimed at treating diseases and medical conditions. Under assessment today on Stock-Callers.com are the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Vascular Biogenics Ltd (NASDAQ: VBLT), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), and Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY). Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
BCRX: 4.20 (+0.04), ALNY: 69.17 (+0.15), HEB: 1.42 (+0.04), VBLT: 4.09 (+0.03)
Alnylam Pharmaceuticals Has Returned 24.1% Since SmarTrend Recommendation (ALNY)
Comtex SmarTrend(R) - Wed Aug 24, 1:13AM CDT
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on July 7th, 2016 at $61.09. In approximately 2 months, Alnylam Pharmaceuticals has returned 24.06% as of today's recent price of $75.79.
ALNY: 69.17 (+0.15)
After Yesterday's Rally of 3.44% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 2:30PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $72.75 to a high of $76.33. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $74.17 on volume of 468,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 69.17 (+0.15)
Uptrend Call Working As Alnylam Pharmaceuticals Stock Rises 21.8% (ALNY)
Comtex SmarTrend(R) - Tue Aug 16, 1:51PM CDT
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on July 7th, 2016 at $61.09. In approximately 1 month, Alnylam Pharmaceuticals has returned 21.80% as of today's recent price of $74.41.
ALNY: 69.17 (+0.15)
Alnylam Pharmaceuticals (ALNY) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 8:54AM CDT
As of late, it has definitely been a great time to be an investor in Alnylam Pharmaceuticals, Inc. (ALNY)
ALNY: 69.17 (+0.15)
27.0% Return Seen to Date on SmarTrend Alnylam Pharmaceuticals Call (ALNY)
Comtex SmarTrend(R) - Mon Aug 08, 1:34PM CDT
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on July 7th, 2016 at $61.09. In approximately 1 month, Alnylam Pharmaceuticals has returned 26.97% as of today's recent price of $77.56.
ALNY: 69.17 (+0.15)
Alnylam Completes Enrollment in ENDEAVOUR Phase 3 Study with Revusiran, an Investigational RNAi Therapeutic for Patients with Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM)
BusinessWire - Mon Aug 08, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has completed enrollment in its ENDEAVOUR Phase 3 study with revusiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM), also known as familial amyloidotic cardiomyopathy (FAC). The ENDEAVOUR trial enrolled 206 patients with hATTR-CM, above the enrollment target of 200 patients. The Company expects to report data from the study in early 2018.
ALNY: 69.17 (+0.15)
Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress
BusinessWire - Thu Aug 04, 3:00PM CDT
--- Presented Clinical Data from Patisiran, Revusiran, Fitusiran, and ALN-CC5 Programs -
ALNY: 69.17 (+0.15)
Jacobs Wins Contract for New Alnylam Biopharmaceutical Manufacturing Facility
BusinessWire - Thu Aug 04, 6:45AM CDT
Jacobs Engineering Group Inc. (NYSE:JEC) announced today it was awarded a contract to provide engineering services and procurement for Alnylam Pharmaceuticals' (Nasdaq: ALNY) new manufacturing facility in Norton, Massachusetts.
JEC: 52.25 (+0.22), ALNY: 69.17 (+0.15)
5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:36AM CDT
How will drug stocks like BMRN, TEVA, REGN and others, scheduled to report on Aug 4, fare this earnings season?
ACAD: 31.59 (-0.51), BMRN: 95.73 (+0.54), ALNY: 69.17 (+0.15), TEVA: 51.22 (+0.32), REGN: 388.64 (-4.76)
Alnylam to Webcast Presentation at Canaccord Genuity Growth Conference
BusinessWire - Tue Aug 02, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 36th Annual Growth Conference on Wednesday, August 10, 2016 at 11:00 a.m. ET at the InterContinental Boston.
ALNY: 69.17 (+0.15)
After Yesterday's Rally of 4.57% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 01, 4:12PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $68.16 to a high of $72.48. Yesterday, the shares gained 4.6%, which took the trading range above the 3-day high of $69.22 on volume of 568,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 69.17 (+0.15)
Alnylam to Webcast Conference Call Discussing Second Quarter 2016 Financial Results
BusinessWire - Thu Jul 28, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter on Thursday, August 4, 2016, after the U.S. financial markets close.
ALNY: 69.17 (+0.15)
Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual "Helping Hands" Community Service Day
BusinessWire - Thu Jun 23, 3:30PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that over 400 of its employees participated in a company-wide community service day today to benefit ten local non-profit organizations including: Boston Nature Center, Cradles to Crayons, Emerald Necklace Conservancy, Friends of Alewife, Habitat Education Center, IMEC America, Cupboard of Kindness, Norton Conservation Land, West End House Boys and Girls Club and Windrush Farms.
ALNY: 69.17 (+0.15)
Biotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx
PR Newswire - Fri Jun 17, 7:50AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and CytRx Corporation (NASDAQ: CYTR). Learn more about these stocks by accessing their free trade alerts at:
MACK: 4.53 (-0.06), ALNY: 69.17 (+0.15), GERN: 2.75 (+0.02), CYTR: 0.57 (-0.01)
Look for Shares of Alnylam Pharmaceuticals to Potentially Rebound after Yesterday's 1.12% Sell Off
Comtex SmarTrend(R) - Mon Jun 13, 3:59PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $61.60 to a high of $63.19. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $62.28 on volume of 605,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALNY: 69.17 (+0.15)
Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis
BusinessWire - Thu Jun 09, 7:00AM CDT
--- Company Expects to Present Initial Clinical Results in Late 2016 and to Initiate a Phase 3 Study in 2017 -
ALNY: 69.17 (+0.15)
Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data
BusinessWire - Fri Jun 03, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss initial results in patients with paroxysmal nocturnal hemoglobinuria (PNH) from the ongoing Phase 1/2 study with ALN-CC5 in a webcast conference call on Saturday, June 11, 2016, at 8:30am ET. Results will be presented earlier that day in an oral presentation at the 21st Congress of the European Hematology Association (EHA) Meeting in Copenhagen, Denmark.
ALNY: 69.17 (+0.15)
After Yesterday's Rally of 7.00% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue May 31, 3:43PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $68.21 to a high of $72.39. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $72.16 on volume of 546,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 69.17 (+0.15)
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
BusinessWire - Tue May 31, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
ALNY: 69.17 (+0.15)
Research Reports Initiation on Biotech Stocks -- Hemispherx Biopharma, Vascular Biogenics, BioCryst Pharma, and Alnylam Pharma
PR Newswire - Mon Aug 29, 7:00AM CDT
The Biotech industry is focused on novel drug development and clinical research aimed at treating diseases and medical conditions. Under assessment today on Stock-Callers.com are the following equities: Hemispherx Biopharma Inc. (NYSE MKT: HEB), Vascular Biogenics Ltd (NASDAQ: VBLT), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), and Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY). Learn more about these stocks by downloading their free report at: http://stock-callers.com/registration
BCRX: 4.20 (+0.04), ALNY: 69.17 (+0.15), HEB: 1.42 (+0.04), VBLT: 4.09 (+0.03)
Alnylam Pharmaceuticals Has Returned 24.1% Since SmarTrend Recommendation (ALNY)
Comtex SmarTrend(R) - Wed Aug 24, 1:13AM CDT
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on July 7th, 2016 at $61.09. In approximately 2 months, Alnylam Pharmaceuticals has returned 24.06% as of today's recent price of $75.79.
ALNY: 69.17 (+0.15)
After Yesterday's Rally of 3.44% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 2:30PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $72.75 to a high of $76.33. Yesterday, the shares gained 3.4%, which took the trading range above the 3-day high of $74.17 on volume of 468,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 69.17 (+0.15)
Uptrend Call Working As Alnylam Pharmaceuticals Stock Rises 21.8% (ALNY)
Comtex SmarTrend(R) - Tue Aug 16, 1:51PM CDT
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on July 7th, 2016 at $61.09. In approximately 1 month, Alnylam Pharmaceuticals has returned 21.80% as of today's recent price of $74.41.
ALNY: 69.17 (+0.15)
Alnylam Pharmaceuticals (ALNY) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 8:54AM CDT
As of late, it has definitely been a great time to be an investor in Alnylam Pharmaceuticals, Inc. (ALNY)
ALNY: 69.17 (+0.15)
27.0% Return Seen to Date on SmarTrend Alnylam Pharmaceuticals Call (ALNY)
Comtex SmarTrend(R) - Mon Aug 08, 1:34PM CDT
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on July 7th, 2016 at $61.09. In approximately 1 month, Alnylam Pharmaceuticals has returned 26.97% as of today's recent price of $77.56.
ALNY: 69.17 (+0.15)
Alnylam Completes Enrollment in ENDEAVOUR Phase 3 Study with Revusiran, an Investigational RNAi Therapeutic for Patients with Hereditary ATTR Amyloidosis with Cardiomyopathy (hATTR-CM)
BusinessWire - Mon Aug 08, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that it has completed enrollment in its ENDEAVOUR Phase 3 study with revusiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM), also known as familial amyloidotic cardiomyopathy (FAC). The ENDEAVOUR trial enrolled 206 patients with hATTR-CM, above the enrollment target of 200 patients. The Company expects to report data from the study in early 2018.
ALNY: 69.17 (+0.15)
Alnylam Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Period Progress
BusinessWire - Thu Aug 04, 3:00PM CDT
--- Presented Clinical Data from Patisiran, Revusiran, Fitusiran, and ALN-CC5 Programs -
ALNY: 69.17 (+0.15)
Jacobs Wins Contract for New Alnylam Biopharmaceutical Manufacturing Facility
BusinessWire - Thu Aug 04, 6:45AM CDT
Jacobs Engineering Group Inc. (NYSE:JEC) announced today it was awarded a contract to provide engineering services and procurement for Alnylam Pharmaceuticals' (Nasdaq: ALNY) new manufacturing facility in Norton, Massachusetts.
JEC: 52.25 (+0.22), ALNY: 69.17 (+0.15)
5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:36AM CDT
How will drug stocks like BMRN, TEVA, REGN and others, scheduled to report on Aug 4, fare this earnings season?
ACAD: 31.59 (-0.51), BMRN: 95.73 (+0.54), ALNY: 69.17 (+0.15), TEVA: 51.22 (+0.32), REGN: 388.64 (-4.76)
Alnylam to Webcast Presentation at Canaccord Genuity Growth Conference
BusinessWire - Tue Aug 02, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 36th Annual Growth Conference on Wednesday, August 10, 2016 at 11:00 a.m. ET at the InterContinental Boston.
ALNY: 69.17 (+0.15)
After Yesterday's Rally of 4.57% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 01, 4:12PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $68.16 to a high of $72.48. Yesterday, the shares gained 4.6%, which took the trading range above the 3-day high of $69.22 on volume of 568,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 69.17 (+0.15)
Alnylam to Webcast Conference Call Discussing Second Quarter 2016 Financial Results
BusinessWire - Thu Jul 28, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter on Thursday, August 4, 2016, after the U.S. financial markets close.
ALNY: 69.17 (+0.15)
Alnylam Pharmaceuticals Supports Greater Boston and Norton Communities with its 2nd Annual "Helping Hands" Community Service Day
BusinessWire - Thu Jun 23, 3:30PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that over 400 of its employees participated in a company-wide community service day today to benefit ten local non-profit organizations including: Boston Nature Center, Cradles to Crayons, Emerald Necklace Conservancy, Friends of Alewife, Habitat Education Center, IMEC America, Cupboard of Kindness, Norton Conservation Land, West End House Boys and Girls Club and Windrush Farms.
ALNY: 69.17 (+0.15)
Biotechnology Equities Technical Review -- Geron, Merrimack Pharma, Alnylam Pharma, and CytRx
PR Newswire - Fri Jun 17, 7:50AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and CytRx Corporation (NASDAQ: CYTR). Learn more about these stocks by accessing their free trade alerts at:
MACK: 4.53 (-0.06), ALNY: 69.17 (+0.15), GERN: 2.75 (+0.02), CYTR: 0.57 (-0.01)
Look for Shares of Alnylam Pharmaceuticals to Potentially Rebound after Yesterday's 1.12% Sell Off
Comtex SmarTrend(R) - Mon Jun 13, 3:59PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $61.60 to a high of $63.19. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $62.28 on volume of 605,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ALNY: 69.17 (+0.15)
Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis
BusinessWire - Thu Jun 09, 7:00AM CDT
--- Company Expects to Present Initial Clinical Results in Late 2016 and to Initiate a Phase 3 Study in 2017 -
ALNY: 69.17 (+0.15)
Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data
BusinessWire - Fri Jun 03, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss initial results in patients with paroxysmal nocturnal hemoglobinuria (PNH) from the ongoing Phase 1/2 study with ALN-CC5 in a webcast conference call on Saturday, June 11, 2016, at 8:30am ET. Results will be presented earlier that day in an oral presentation at the 21st Congress of the European Hematology Association (EHA) Meeting in Copenhagen, Denmark.
ALNY: 69.17 (+0.15)
After Yesterday's Rally of 7.00% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue May 31, 3:43PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $68.21 to a high of $72.39. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $72.16 on volume of 546,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 69.17 (+0.15)
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
BusinessWire - Tue May 31, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
ALNY: 69.17 (+0.15)
(0)
(0)